Menlo Ventures in 2026: A $3 Billion Fund, a $14 Billion Anthropic Stake, and the Deals It's Leading Now

Menlo Ventures raised $3 billion in June 2026 — reportedly its largest fund in 50 years — and has since led or joined at least six AI funding rounds worth a combined $1.8 billion.

Menlo turned 50 in 2026, and it marked the anniversary by announcing the biggest capital raise in its history on June 23, 2026. The raise was possible largely because of one bet: Menlo's roughly $1 billion invested in Anthropic is now worth an estimated $14 billion. This is what the firm actually did with the new capital and its existing portfolio between June and September 2026 — the deals it led, the deals it merely joined, and the parts of the story that don't show up in the fund-size headline.

Menlo Ventures Investments 2026: Inside the $3 Billion Bet

Menlo Ventures investments in 2026 span a $3 billion fund raise, a $750 million Anthropic bet that turned into a $14 billion stake, and at least six new or follow-on AI rounds between July and September. The firm split its new capital into Menlo Ventures XVII (seed through Series A) and Menlo Inflection IV (Series B and growth), pushing total assets under management to roughly $8.5 billion — a firm founded in 1976 that spent most of its history as a generalist early-stage shop before re-anchoring almost entirely around AI.

According to TechCrunch's reporting on the raise, Menlo initially filed to target a combined $1.5 billion across the two vehicles — $700 million for Fund XVII and $800 million for Inflection IV, per a September 2025 SEC filing — before ultimately closing at double that target. Limited partners evidently wanted more exposure to a firm that had already proven, on paper, that a concentrated AI bet could work.

The Anthropic Payoff That Funded Everything

Menlo first backed Anthropic in 2023, then led the company's $750 million Series D — reported by CNBC in December 2023 — which closed in early 2024 at an $18.4 billion valuation. Anthropic has since raised repeatedly at steep markups, and Menlo's total position, spread across four separate fund vehicles (MV XV, MV XVI, Inflection III, and Inflection IV) plus a special purpose vehicle, is now worth an estimated $14 billion, according to a July 16, 2026 report from Newcomer. That single position is reportedly around 10 times larger than Menlo's next-biggest holding in any other company — a concentration few venture firms would admit to voluntarily, but one Menlo has leaned into as its core marketing story.

Newcomer's reporting also states that the Anthropic markup has pushed the internal rate of return on Menlo's 2023 and 2026-vintage funds above 40%. That figure is a paper mark, not a realized return — Menlo hasn't sold down the Anthropic position, so the IRR reflects Anthropic's rising valuation on subsequent rounds rather than cash actually returned to limited partners. One read on this: a 40%+ IRR built almost entirely on one unrealized holding is a very different risk profile than the same IRR spread across a diversified book, even if the number on the LP report looks identical.

Inside the Menlo Anthology Fund, Where Claude Helps Pick the Startups

Menlo's most distinctive 2026 vehicle isn't the flagship fund — it's the Menlo Anthology Fund, a $100 million program the firm launched jointly with Anthropic in July 2024. Startups building on Anthropic's models can apply for a check starting around $100,000, and Anthropic's Claude models are used to help Menlo's team surface and screen applicants, alongside standard perks like API credits and access to Anthropic executives. It's an unusual structure: the AI lab Menlo bet the firm on is now also functioning as part of Menlo's own deal-sourcing pipeline.

By 2026, the Anthology Fund had deployed roughly $250 million across more than 60 companies — a 2.5x scale-up from its original $100 million size — with two completed exits and one announced acquisition. Fintool, an AI financial-research platform, was acquired by Microsoft on April 18, 2026. Graphite, a code-review startup used by Shopify, Snowflake, and Figma, was acquired by Cursor in 2026 as Cursor's third acquisition. And Astrix Security — which Menlo had backed with a $45 million Series B in December 2024 — agreed to be acquired by Cisco for roughly $400 million, a deal that Cisco announced on May 3, 2026 and closed June 29, 2026.

Menlo's 2026 Deal Sheet: Led vs. Just Along for the Ride

Not every 2026 deal on Menlo's books is one it priced. Some rounds it led outright; others it simply followed its money into as an existing backer inside a much larger syndicate. That distinction matters for reading the firm's actual influence — leading a round means setting terms and taking a board seat; joining a $300-400 million growth round as one of six or seven names means writing a check and getting information rights, not control.

Sources: Bloomberg, CNBC, TechCrunch, Fortune, GlobeNewswire, and SiliconANGLE reporting on each round, 2024–2026. Anthropic Series D valuation reflects the round's close price, not Anthropic's current valuation.

Of the seven positions above, Menlo led or co-led three — Anthropic, Wispr Flow, and Lovable — and led one small seed check solo (Cheiron). The other three were follow-on participations inside syndicates led by other firms: Andreessen Horowitz priced Gimlet Labs, DST Global priced Higgsfield, and Index Ventures priced Chai Discovery. That 3-led-to-3-joined split is a more accurate picture of Menlo's 2026 activity than either "it led everything" or "it's just riding Anthropic's coattails" — both of which are the two lazy readings this data tends to invite.

The three deals Menlo joined rather than led each show a different kind of syndicate the firm is willing to sit inside. Higgsfield's $400 million round pulled in a genuinely unusual mix of backers — Goldman Sachs Alternatives Growth Equity, Fifth Wall (normally a real-estate-focused fund), telecom arm NTT DOCOMO Ventures, and Intel Capital alongside Menlo — a signal that investors are pricing AI video as infrastructure for marketing and media rather than a novelty consumer app. Chai Discovery's round is anchored by paying pharmaceutical customers rather than pure speculation: Eli Lilly, Pfizer, and Novartis were already customers of the company's molecular-design models before Index Ventures priced the $400 million Series C. And Gimlet Labs' $300 million round, which valued the multi-silicon AI inference platform at $3 billion just six months after an $80 million Series A priced it at $980 million, brought in strategic chip players M12 (Microsoft's venture arm) and Arm alongside Menlo — a sign that inference-layer infrastructure is drawing capital from both traditional VCs and the hardware companies whose chips it runs on.

What Menlo Is Actually Betting On, Sector by Sector

The 2026 deal sheet reveals a thesis wider than "AI foundation models." Beyond Anthropic itself, Menlo's active checks span AI application layers that sit on top of frontier models: voice interfaces (Wispr Flow) in the same category as voice-generation tools like ElevenLabs, AI-generated software (Lovable), AI video generation (Higgsfield), computational biology and drug discovery (Chai Discovery and the much smaller Cheiron), and inference infrastructure that makes those applications cheaper to run at scale (Gimlet Labs). That spread matches what Menlo's own June 2026 fund announcement described — investing "across the AI stack," from infrastructure through frontier labs to consumer and enterprise applications — rather than a narrow bet on any single layer.

Stage-wise, the split between Fund XVII and Inflection IV shows up clearly in the check sizes: Cheiron's $8 million seed and the Anthology Fund's sub-$1 million entry checks sit at the very early end Fund XVII is built for, while the $280-400 million rounds in Wispr Flow, Lovable, Higgsfield, Chai Discovery, and Gimlet Labs are the kind of late-stage, high-conviction markups Inflection IV exists to chase. Menlo is running both ends of the barbell simultaneously, using Anthology as a volume play for early optionality and the growth fund to defend positions once a company is clearly working.

Cheiron is the clearest example of the early end of that barbell. The $8 million seed, announced July 22, 2026, backs a company building what it calls the operating system for drug programs — software meant to coordinate the sprawling, multi-year process of running a clinical drug candidate through discovery and trials. Menlo led the round solo, and the check drew industry-veteran backers including Moderna co-founder Robert Langer and former Pfizer Chief Medical Officer Freda Lewis-Hall, giving a tiny seed round outsized credibility in a sector — biotech software — where clinical and regulatory judgment matters as much as the code itself.

What the Headline Misses

A $14 billion Anthropic stake and a 40%+ IRR make for a clean story, but three caveats sit underneath it. First, concentration risk: with one position reportedly worth roughly 10 times Menlo's next-largest holding, the firm's headline performance is a bet on one company's continued ability to raise at ever-higher valuations, not evidence of broad-based stock-picking skill across its book. If Anthropic's growth trajectory stalls or its valuation resets, Menlo's reported IRR resets with it.

Second, three of the six 2026 deals in the table above were led by other firms — Andreessen Horowitz, DST Global, and Index Ventures each priced a round Menlo simply joined. Being in the syndicate is not the same as setting the terms, and a firm's press coverage tends to credit "Menlo-backed" deals without always distinguishing lead from follower. Third, the Anthology Fund's headline count — 60+ companies, two exits — is still a small, early-innings sample; most of that portfolio has neither exited nor been marked up or down in any publicly disclosed way, so it's too soon to call the vehicle's early exits (a $400 million Cisco deal, an undisclosed Microsoft acquisition, and an all-stock-and-cash Cursor deal) a validated performance history rather than a promising start.

The Bottom Line for Founders and LPs

For founders: Menlo in 2026 is writing two very different kinds of checks — sub-$1 million Anthology Fund bets for anyone building seriously on Claude, and $8 million-plus seed-to-growth checks for companies it wants to lead. If you're building an AI application and want fast, low-friction early capital plus Anthropic access, Anthology is the more realistic door; if you want Menlo to lead and set terms, the bar is closer to Cheiron's or Wispr Flow's profile — a working product and a growth curve the firm can underwrite alone. Founders raising a growth round Menlo is likely to join without leading should expect the firm to defer on price and terms to whichever fund is setting them, which in 2026 has meant Andreessen Horowitz, DST Global, and Index Ventures.

For LPs evaluating the firm, the honest read is that Menlo's 2023 and 2026 vintage funds look extraordinary on paper largely because of one concentrated, still-unrealized position — a result worth studying for the sourcing instinct it rewards, but not yet proof that the next fund's non-Anthropic bets, including the six 2026 deals above, will repeat it. The Anthology Fund's early exits are a genuinely useful signal that Menlo's smaller, faster checks can produce real outcomes independent of Anthropic's own valuation path, but two completed exits and one pending acquisition out of 60-plus companies is still a small enough sample that it belongs in the "promising" column rather than the "proven" one.